Terasaki Institute for Biomedical Innovation and Tetratherix™ Form Collaboration

LOS ANGELES: LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix™, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications. Tetramatrix exhibits superior injectability, responsiveness to body...

Click to view original post